prikaz prve stranice dokumenta Does the Efficacy of Semaglutide Treatment Differ between Low-Risk and High-Risk Subgroups of Patients with Type 2 Diabetes and Obesity Based on SCORE2, SCORE2-Diabetes, and ASCVD Calculations?
  Preuzmi
PDF 3.15 MB
Znanstveni rad - Izvorni znanstveni rad
Does the Efficacy of Semaglutide Treatment Differ between Low-Risk and High-Risk Subgroups of Patients with Type 2 Diabetes and Obesity Based on SCORE2, SCORE2-Diabetes, and ASCVD Calculations?
Diabetology, 5 (2024), 1; 26-39. https://doi.org/10.3390/diabetology5010003
Matovinović, Martina; Belančić, Andrej; Jug, Juraj; Mustač, Filip; Sirovica, Maja; Santini, Mihovil; Bošnjaković, Anja; Lovrić, Mario; Lovrić Benčić, Martina

Citiranost:
,
Citirajte ovaj rad

Matovinović, M., Belančić, A., Jug, J., Mustač, F., Sirovica, M., Santini, M. ... Lovrić Benčić, M. (2024). Does the Efficacy of Semaglutide Treatment Differ between Low-Risk and High-Risk Subgroups of Patients with Type 2 Diabetes and Obesity Based on SCORE2, SCORE2-Diabetes, and ASCVD Calculations?. Diabetology, 5. (1), 26-39. doi: 10.3390/diabetology5010003

Matovinović, Martina, et al. "Does the Efficacy of Semaglutide Treatment Differ between Low-Risk and High-Risk Subgroups of Patients with Type 2 Diabetes and Obesity Based on SCORE2, SCORE2-Diabetes, and ASCVD Calculations?." Diabetology, vol. 5, br. 1, 2024, str. 26-39. https://doi.org/10.3390/diabetology5010003

Matovinović, Martina, Andrej Belančić, Juraj Jug, Filip Mustač, Maja Sirovica, Mihovil Santini, Anja Bošnjaković, Mario Lovrić i Martina Lovrić Benčić. "Does the Efficacy of Semaglutide Treatment Differ between Low-Risk and High-Risk Subgroups of Patients with Type 2 Diabetes and Obesity Based on SCORE2, SCORE2-Diabetes, and ASCVD Calculations?." Diabetology 5, br. 1 (2024): 26-39. https://doi.org/10.3390/diabetology5010003

Matovinović, M., et al. (2024) 'Does the Efficacy of Semaglutide Treatment Differ between Low-Risk and High-Risk Subgroups of Patients with Type 2 Diabetes and Obesity Based on SCORE2, SCORE2-Diabetes, and ASCVD Calculations?', Diabetology, 5(1), str. 26-39. doi: 10.3390/diabetology5010003

Matovinović M, Belančić A, Jug J, Mustač F, Sirovica M, Santini M, i sur.. Does the Efficacy of Semaglutide Treatment Differ between Low-Risk and High-Risk Subgroups of Patients with Type 2 Diabetes and Obesity Based on SCORE2, SCORE2-Diabetes, and ASCVD Calculations?. Diabetology [Internet]. 04.01.2024. [pristupljeno 24.02.2025.];5(1):26-39. doi: 10.3390/diabetology5010003

M. Matovinović, et al., "Does the Efficacy of Semaglutide Treatment Differ between Low-Risk and High-Risk Subgroups of Patients with Type 2 Diabetes and Obesity Based on SCORE2, SCORE2-Diabetes, and ASCVD Calculations?", Diabetology, vol. 5, br. 1, str. 26-39, Siječanj 2024. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:769094. [Citirano: 24.02.2025.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:184:769094
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Does the Efficacy of Semaglutide Treatment Differ between Low-Risk and High-Risk Subgroups of Patients with Type 2 Diabetes and Obesity Based on SCORE2, SCORE2-Diabetes, and ASCVD Calculations?
AutorMartina Matovinović
AutorAndrej Belančić
AutorJuraj Jug
AutorFilip Mustač
AutorMaja Sirovica
AutorMihovil Santini
AutorAnja Bošnjaković
AutorMario Lovrić
AutorMartina Lovrić Benčić
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Katedra za farmakologiju)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Interna medicina
Sažetak (engleski)
Background: Diabetes is the primary contributor to cardiovascular disease risk, and when combined with obesity, it further underscores the significance of cardiovascular risk assessment. Methods: A retrospective study of 64 patients with type 2 diabetes (T2D) and obesity on once-weekly subcutaneous semaglutide stratified by cardiovascular risk categories determined using the SCORE2/SCORE2-OP, SCORE2-Diabetes, and ASCVD score calculations. We compare the differences between groups (ASCVD: low +... Više borderline + intermediate versus high-risk group; SCORE2/SCORE2-OP: low + moderate versus high + very high-risk group and SCORE2-Diabetes: low + moderate versus high + very high-risk group) in terms of change from baseline in body mass index (BMI) and HbA1c and weight loss outcomes. Results: Patients in the high-risk group, according to ASCVD risk score, had statistically better results in weight loss ≥ 3%, ≥5%, and ≥10% compared to ASCVD low + borderline + intermediate and without difference regarding HbA1c. According to SCORE2/SCORE2-OP, the high + very high-risk group had statistically better HbA1c and weight loss results but only for ≥5% versus the low + moderate risk group. Based on the score SCORE2-Diabetes, the high + very high-risk group had statistically significant better results in lowering HbA1c and weight loss but only for ≥5% versus the low + moderate risk group. Conclusions: To the best of our knowledge, this study represents the initial investigation linking glycemic control and weight reduction outcomes in individuals with T2D and obesity treated with once-weekly semaglutide stratified by cardiovascular risk categories determined using the SCORE2/SCORE2-OP, SCORE2-Diabetes and ASCVD score calculations. Sakrij dio sažetka
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaDiabetology
Brojčani podacivol. 5, br. 1, str. 26-39
e-ISSN2673-4540
DOIhttps://doi.org/10.3390/diabetology5010003
URN:NBNurn:nbn:hr:184:769094
Datum objave publikacije2024-01-04
URL dokumentahttps://www.mdpi.com/2673-4540/5/1/3
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 4.0 međunarodna (CC BY 4.0)
Datum i vrijeme pohrane2024-01-05 12:24:56
accessibility

closePristupačnostrefresh

Ako želite spremiti trajne postavke, kliknite Spremi, ako ne - vaše će se postavke poništiti kad zatvorite preglednik.